- United Therapeutics (UTHR, Financial) to present at the American Thoracic Society Conference in San Francisco, May 16-21, 2025.
- Key presentations include phase 3 data on ralinepag and inhaled treprostinil.
- UTHR is sponsoring major events such as the Respiratory Innovation Summit and the Jenesis Innovative Research Awards Ceremony.
United Therapeutics Corporation (UTHR), a public benefit corporation, has announced its participation in the American Thoracic Society (ATS) 2025 International Conference in San Francisco, scheduled from May 16-21, 2025. The company aims to showcase a comprehensive range of clinical data from its commercial and development portfolios.
A major highlight at the conference will be the presentation of interim long-term data from the ralinepag phase 3 ADVANCE EXTENSION open-label study. This presentation will explore the potential of ralinepag's once-daily dosing to alter the therapeutic landscape for pulmonary arterial hypertension.
Another focus will be on the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil for idiopathic pulmonary fibrosis. These findings will be shared through thematic poster sessions, mini-symposia, and discussion sessions.
In addition to the presentations, United Therapeutics is sponsoring several pivotal events at the conference. These include the Respiratory Innovation Summit, the ATS Research Program Benefit Networking Event, and the prestigious Jenesis Innovative Research Awards Ceremony.
Andrew Nelsen, PharmD, Vice President of Global Medical Affairs at United Therapeutics, emphasized the importance of the company's participation at ATS, highlighting that it provides a platform to present the latest data on key products and innovations aimed at addressing unmet medical needs.
